Igniva analyses biological, chemical and clinical datasets, knowledge bases and AI models while human experts provide feedback
Artificial intelligence developer Aganitha AI has unveiled Igniva, a suite of AI agents for therapeutic design and research.
The suite, unveiled at MD&M West 2025, is designed to accelerate research and development by filling in gaps between data acquisition and clinical application.
"Igniva brings a new level of reasoning and explainability to AI-driven therapeutic research,” said Aganitha co-founder and managing director Prasad Chodavarapu.
“Its multi-scalar systems biology and physics-informed chemistry methods enable a deeper understanding of disease mechanisms and drug interactions. By providing interpretable insights, Igniva™ supports researchers in designing and optimising therapeutics with greater confidence and efficiency.”
Alongside the input of human experts, Igniva analyses biological, chemical and clinical datasets, knowledge bases and AI models. Using this data, the suite generates insights and refines hypotheses.
Igniva’s interconnected structure is formed from agents grouping into foundational, domain-specific and role-based categories such as hypothesis generators. The agents can share insights, refine predictions and refine decision-making efficiency across the therapeutic development process.
The modular, scalable suite incorporates an array of technologies:
-
Foundational Models for Biology & Chemistry
-
Advancements in High-Throughput Biology & Chemistry Experimentation
-
Multi-Modal AI Integrating Molecular, Imaging, and Clinical Insights
-
GenAI-Driven Therapeutic Design & Optimization
-
Quantum Chemistry Feature-Driven Models for Characterization and Optimization of Therapeutic Candidates
-
LLM-Powered Compliance and Regulatory Workflows
These resources help Igniva to provide researchers with a more robust understanding across multiple disease areas.
“AI adoption in biopharma is no longer optional—it's critical. The race to first-in-class and best-in-class therapies demands faster, smarter, and more holistic decision-making,” said Aganitha co-founder and CEO Vikram Duvvoorki.
“Igniva equips researchers with the tools to leverage broader, deeper scientific insights, accelerating breakthroughs and keeping them ahead in a rapidly evolving landscape.”
